Checkpoint inhibitors immunotherapy was a breakthrough in anti-Tumor treatments. Anti-PD-1 monoclonal antibodies are now a standard of treatment for advanced melanoma patients, with a 3-year overall survival of over 50% and a low rate (<20%) of severe toxicities in the phase 3 studies. The aim of this review was to report the most important updates on anti-PD-1 drug pembrolizumab from ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) 2017 Annual Meetings.
|Translated title of the contribution||Pembrolizumab for the treatment of melanoma: Updates and perspectives|
|Number of pages||4|
|Journal||Recenti Progressi in Medicina|
|Publication status||Published - Dec 1 2017|
ASJC Scopus subject areas